ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
This strategic collaboration will enable continued innovation in cancer care
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug
Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained
The company to receive upfront and milestone payments, in addition to royalties
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
Subscribe To Our Newsletter & Stay Updated
